Obesity Medicine

Find details on optimizing diabetes care in primary care settings, benefits of GLP-1RAs for patients with HF and diabetes, and tirzepatide use for obesity-related OSA.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

More than 50% of patients with MASH receiving 1 of 3 doses of tirzepatide achieved MASH resolution without worsening of fibrosis vs placebo, according to data from phase 2 study.

In contrast, men did not face the same increased risk of cerebrovascular disease later in life, reported authors of a new study.

Your daily dose of the clinical news you may have missed.

There are lots of products in development for weight loss and to treat other metabolic diseases which means more options for more people.

Despite its limitations for use in other populations, a high BMI proved a very good predictor of dangerous fat mass index in youth aged 8 to 19 years in this study.

The interactive tool provides clinicians and patients a real-time look at GLP-1RA availability.

Shagun Bindlish, MD, discusses the complex interplay between obesity and mental health conditions and how sex is a potential moderating factor.

DDW 2024. Offspring with both parents with overweight had a nearly 3-fold increased risk of MASLD in young adulthood, according to new data.

In the phase 1b trial, treatment with once-weekly subcutaneous CT-388 led to a statistically significant mean placebo-adjusted weight loss of nearly 20%.

Your daily dose of the clinical news you may have missed.

Analyses of the SELECT trial found mean weight loss of 10.2% sustained for 4 years and comparable CV benefit with weight loss greater or less than 5%, or even weight gain.

Results also showed that older adults, men, and Black adults face an increased risk of advanced stages of CKM syndrome.

Your daily dose of the clinical news you may have missed.

Naim Alkhouri, MD, a transplant hepatologist and a resmetirom investigator, talks here about the life-changing impact the drug will have for all touched by MASH.

Primary care is where early detection and treatment of liver disease should begin and as Dr Alkhouri highlights here, all the right tools are already at hand.

The national study on the true prevalence of metabolic dysfunction-associated liver disease is essential to screening, prevention, and treatment efforts, says AFL CEO Stiehl.

Adults receiving semaglutide for the first time achieved weight loss of 14.3% at 12 months vs 10.6% among those who had previously taken a different antiobesity drug.

Your daily dose of the clinical news you may have missed.

Among persons with COPD whose BMI decreased over a 4-year follow-up, mortality risk rose 70% compared with those whose BMI remained the same, researchers reported.

With the rise in demand for newer antiobesity medications, clinicians may face more questions from patients. Here, a primer on the drawbacks and benefits to keep in mind.

Tirzepatide reduced OSA symptoms and body weight in study participants with severe OSA and obesity, regardless of use of positive airway pressure therapy.

Results of a recent study support the importance of lifestyle interventions to reduce the burden of breathlessness in middle-aged adults.